Strengthening its international ties, BioNJ signed an MOU (Memorandum of Understanding) with Belgian Biotech organization FlandersBio at the 2010 BIO International Convention in Chicago.
BioNJ Board of Trustees Chairman and Celgene Corporation Chairman Dr. Sol J. Barer spoke on May 5, 2011 at Knowledge for Growth in Ghent, Belgium. Dr. Barer was introduced by BioNJ President Debbie Hart. Please click the above logo for more information about the 2013 conference.
A respected global leader in the biotechnology industry, Flanders is a natural and outstanding counterpart to New Jersey. While BioNJ and FlandersBio have had a productive, informal relationship for many years, the signing of an MOU formalizes the partnership, and ensures the countinued success of both FlandersBio and BioNJ.
“As the biotechnology industry continues to evolve, finding areas for mutual cooperation at an international level is becoming increasingly more important,” said Debbie Hart, President of BioNJ. “The signing of the MOU with FlandersBio represents an important step in our goal of establishing a strong international presence for our members.”
“We are delighted that Flanders has stepped up its trans-Atlantic partnerships through New Jersey, a state that is in many ways very similar to ours and we believe that this new initiative will be very beneficial to both states in the future,” said Jan Wauters, Technology Attaché at Flanders Investment and Trade.
Belgium and Flanders Fast Facts:
Flanders, the northern region of Belgium, boasts a mature life science industry, prestigious academic institutions and hospitals, and productive research centers. Truly at the crossroads of Western Europe, both NATO and the European Union are headquartered in Brussels, Belgium’s cosmopolitan capital city. While French, Dutch, and German are each official languages, English is widely spoken, making Flanders a desirable and accessible region for US companies.
FlandersBio is the umbrella organization for the Life Sciences and Biotechnology sector in Flanders, and is a dynamic non-profit, fee-based organization with more than 210 members that supports and facilitates the sector’s sustained development. By organizing networking activities, FlandersBio builds bridges between the different actors and by actively stimulating innovation and R&D, FlandersBio creates an added value for the sector as a whole.
Latest News from FlandersBio:
Unable to display feed at this time.